NIAID Seeks Volunteers for Clinical Studies on Newly Diagnosed Type 1 Diabetes

NIAID Seeks Volunteers for Clinical Studies on Newly Diagnosed Type 1 Diabetes

The National Institute of Allergy and Infectious Diseases (NIAID), in collaboration with the Immune Tolerance Network, seeks volunteers for clinical studies that aim to halt or slow the progression of type 1 diabetes in people within 100 days of diagnosis. These studies are being conducted by research teams across the United States.


Inducing Remission in Type 1 Diabetes With Alefacept – T1DAL Study - NOW OPEN!

This study seeks volunteers ages 12 to 35 to test whether the drug alefacept will slow or halt destruction of insulin-producing beta cells in the pancreas. Read more about the T1DAL study and find site locations on ClinicalTrials.gov [Inducing Remission in Type 1 Diabetes With Alefacept - Full Text View - ClinicalTrials.gov] and at the study Web site [Home | T1DAL].

A Research Trial of Aralast in New Onset Diabetes – RETAIN Study

This study seeks volunteers ages 8 to 35 to investigate the effect of intravenous Alpha-1 Antitrypsin (AAT, Aralast NP) on preserving insulin-producing beta cell function and slowing the progression of type 1 diabetes. Read more about the RETAIN study and find site locations on ClinicalTrials.gov [A Research Trial of Aralast in New Onset Diabetes (RETAIN) - Part I - Full Text View - ClinicalTrials.gov] and at the study Web site [Home | T1DAL].